Tags

Type your tag names separated by a space and hit enter

A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
J Clin Gastroenterol 2017; 51(1):e5-e10JC

Abstract

GOALS

We assessed the efficacy of a probiotic mixture of Bifidobacterium infantis M-63, breve M-16V, and longum BB536 in improving abdominal pain (AP) and quality of life (QoL) in children with irritable bowel syndrome (IBS) and functional dyspepsia (FD).

BACKGROUND

AP-associated functional gastrointestinal disorders, particularly IBS and FD, are common in pediatrics, and no well-established treatment is currently available. Although probiotics have shown promising results in adults, data in children are heterogeneous.

STUDY

Forty-eight children with IBS (median age, 11.2 y; range, 8 to 17.9 y) and 25 with FD (age, 11.6 y; range, 8 to 16.6 y) were randomized to receive either a mixture of 3 Bifidobacteria or a placebo for 6 weeks. After a 2-week "washout" period, each patient was switched to the other group and followed up for further 6 weeks. At baseline and follow-up, patients completed a symptom diary and a QoL questionnaire. AP resolution represented the primary outcome parameter.

RESULTS

In IBS, but not in FD, Bifidobacteria determined a complete resolution of AP in a significantly higher proportion of children, when compared with placebo (P=0.006), and significantly improved AP frequency (P=0.02). The proportion of IBS children with an improvement in QoL was significantly higher after probiotics than after placebo (48% vs. 17%, P=0.001), but this finding was not confirmed in FD.

CONCLUSIONS

In children with IBS a mixture of Bifidobacterium infantis M-63, breve M-16V, and longum BB536 is associated with improvement in AP and QoL. These findings were not confirmed in FD subjects. Trial identifier: NCT02566876 (http://www.clinicaltrial.gov).

Authors+Show Affiliations

*Department of Translational Medical Sciences, Section of Pediatrics, Federico II University †Department of Woman, Child, and General and Specialistic Surgery, Second University of Naples, Naples ‡Department of Pediatrics, University of Foggia, Foggia, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

27306945

Citation

Giannetti, Eleonora, et al. "A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial." Journal of Clinical Gastroenterology, vol. 51, no. 1, 2017, pp. e5-e10.
Giannetti E, Maglione M, Alessandrella A, et al. A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. J Clin Gastroenterol. 2017;51(1):e5-e10.
Giannetti, E., Maglione, M., Alessandrella, A., Strisciuglio, C., De Giovanni, D., Campanozzi, A., ... Staiano, A. (2017). A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Journal of Clinical Gastroenterology, 51(1), pp. e5-e10.
Giannetti E, et al. A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. J Clin Gastroenterol. 2017;51(1):e5-e10. PubMed PMID: 27306945.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. AU - Giannetti,Eleonora, AU - Maglione,Marco, AU - Alessandrella,Annalisa, AU - Strisciuglio,Caterina, AU - De Giovanni,Donatella, AU - Campanozzi,Angelo, AU - Miele,Erasmo, AU - Staiano,Annamaria, PY - 2016/6/17/pubmed PY - 2017/12/12/medline PY - 2016/6/17/entrez SP - e5 EP - e10 JF - Journal of clinical gastroenterology JO - J. Clin. Gastroenterol. VL - 51 IS - 1 N2 - GOALS: We assessed the efficacy of a probiotic mixture of Bifidobacterium infantis M-63, breve M-16V, and longum BB536 in improving abdominal pain (AP) and quality of life (QoL) in children with irritable bowel syndrome (IBS) and functional dyspepsia (FD). BACKGROUND: AP-associated functional gastrointestinal disorders, particularly IBS and FD, are common in pediatrics, and no well-established treatment is currently available. Although probiotics have shown promising results in adults, data in children are heterogeneous. STUDY: Forty-eight children with IBS (median age, 11.2 y; range, 8 to 17.9 y) and 25 with FD (age, 11.6 y; range, 8 to 16.6 y) were randomized to receive either a mixture of 3 Bifidobacteria or a placebo for 6 weeks. After a 2-week "washout" period, each patient was switched to the other group and followed up for further 6 weeks. At baseline and follow-up, patients completed a symptom diary and a QoL questionnaire. AP resolution represented the primary outcome parameter. RESULTS: In IBS, but not in FD, Bifidobacteria determined a complete resolution of AP in a significantly higher proportion of children, when compared with placebo (P=0.006), and significantly improved AP frequency (P=0.02). The proportion of IBS children with an improvement in QoL was significantly higher after probiotics than after placebo (48% vs. 17%, P=0.001), but this finding was not confirmed in FD. CONCLUSIONS: In children with IBS a mixture of Bifidobacterium infantis M-63, breve M-16V, and longum BB536 is associated with improvement in AP and QoL. These findings were not confirmed in FD subjects. Trial identifier: NCT02566876 (http://www.clinicaltrial.gov). SN - 1539-2031 UR - https://www.unboundmedicine.com/medline/citation/27306945/A_Mixture_of_3_Bifidobacteria_Decreases_Abdominal_Pain_and_Improves_the_Quality_of_Life_in_Children_With_Irritable_Bowel_Syndrome:_A_Multicenter_Randomized_Double_Blind_Placebo_Controlled_Crossover_Trial_ L2 - http://Insights.ovid.com/pubmed?pmid=27306945 DB - PRIME DP - Unbound Medicine ER -